血浆EBV DNA用于鼻咽癌的系统综述与推荐
作者建议将其纳入筛查、治疗前预后评估与治疗策略制定、根治性治疗中监测、治疗后随访早期发现复发及挽救治疗监测,但检测方法需标准化后才能全球推广。
要点
- 血浆EBV DNA可考虑用于鼻咽癌筛查、治疗前预后评估与治疗策略制定。
- 根治性治疗中监测、治疗后随访及挽救治疗监测也可考虑纳入血浆EBV DNA。
- 检测方法尚未统一,需 harmonisation 后才能全球应用。
核心结论
- 基于证据等级与推荐强度评估,支持将血浆EBV DNA纳入国际指南的上述临床环节。
- 检测方法学问题必须解决后才能全球推广。
主要发现
- 共81篇文章符合纳入标准。
- 血浆EBV DNA在筛查、治疗前预后评估与治疗策略制定、根治性治疗中监测、治疗后随访早期发现复发及挽救治疗监测中具有应用价值。
临床怎么用
- 可考虑将血浆EBV DNA用于鼻咽癌筛查、治疗前预后评估与治疗策略制定。
- 可考虑在根治性治疗中监测、治疗后随访早期发现复发及挽救治疗监测中使用血浆EBV DNA。
局限性
- 检测方法需要 harmonisation 以实现一致的可比性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Nasopharyngeal carcinoma (NPC) is an endemic malignancy in Southeast Asia, particularly Southern China. The classical non-keratinising cell type is almost unanimously associated with latent Epstein-Barr virus (EBV) infection. Circulating plasma EBV DNA can be a useful biomarker in various clinical aspects, but comprehensive recommendations and international guidelines are still lacking. We conducted a systematic review of all original articles on the clinical application of plasma EBV DNA for NPC; we further evaluated its strengths and limitations for consideration as standard recommendations. METHODS: The search terms 'nasopharyngeal OR nasopharynx', and 'plasma EBV DNA OR cell-free EBV OR cfEBV' were used to identify full-length articles published up to December 2020 in the English literature. Three authors independently reviewed the article titles, removed duplicates and reviewed the remaining articles for eligibility. RESULTS: A total of 81 articles met the eligibility criteria. Based on the levels of evidence and grades of recommendation assessed, it is worth considering the inclusion of plasma EBV DNA in screening, pre-treatment work-up for enhancing prognostication and tailoring of treatment strategy, monitoring during radical treatment, post-treatment surveillance for early detection of relapse, and monitoring during salvage treatment for recurrent or metastatic NPC. One major limitation is the methodology of measurement requiring harmonisation for consistent comparability. CONCLUSIONS: The current comprehensive review supports the inclusion of plasma EBV DNA in international guidelines in the clinical aspects listed, but methodological issues must be resolved before global application.
引用
- Lee AWM, Lee VHF, Ng WT, et al. A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. Eur J Cancer. 2021. PMID: 34153713. doi:10.1016/j.ejca.2021.05.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。